Nedaplatin for injection has mainly antitumor effects, and this drug may lead to the formation of ionotropic substances after entering cells. Its mode of action is similar to that of cisplatin. Nedaplatin belongs to the analogues of cisplatin, which can inhibit the replication of tumor cell DNA and thus produce antitumor activity. In clinical practice, nedaplatin for injection is mainly used in solid tumors such as head and neck cancer, small cell lung cancer, non-small cell lung cancer, and esophageal cancer. The main adverse effect of this drug is myelosuppression, which may manifest as a decrease in white blood cells, platelets, and hematocrit, so blood count should be monitored regularly during the drug administration. Other more common adverse reactions mainly include gastrointestinal symptoms such as nausea, vomiting, and loss of appetite. In addition, individual patients may also experience abnormal liver and kidney function. In conclusion, nedaplatin for injection has mainly anti-tumor effects.